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Abstract
Background: Pancreas organogenesis is the result of well-orchestrated and balanced activities of transcription factors. The
homeobox transcription factor PDX-1 plays a crucial role in the development and function of the pancreas, both in the
maintenance of progenitor cells and in determination and maintenance of differentiated endocrine cells. However, the
activity of homeobox transcription factors requires coordination with co-factors, such as PBX and MEIS proteins. PBX and
MEIS proteins belong to the family of three amino acid loop extension (TALE) homeodomain proteins. In a previous study
we found that PDX-1 negatively regulates the transcriptional activity of the ductal specific keratin 19 (Krt19). In this study,
we investigate the role of different domains of PDX-1 and elucidate the functional interplay of PDX-1 and MEIS1 necessary
for Krt19 regulation.
Methodology/Principal Findings: Here, we demonstrate that PDX-1 exerts a dual manner of regulation of Krt19
transcriptional activity. Deletion studies highlight that the NH2-terminus of PDX-1 is functionally relevant for the down-
regulation of Krt19, as it is required for DNA binding of PDX-1 to the Krt19 promoter. Moreover, this effect occurs
independently of PBX. Second, we provide insight on how PDX-1 regulates the Hox co-factor MEIS1 post-transcriptionally.
We find specific binding of MEIS1 and MEIS2 to the Krt19 promoter using IP-EMSA, and siRNA mediated silencing of Meis1,
but not Meis2, reduces transcriptional activation of Krt19 in primary pancreatic ductal cells. Over-expression of PDX-1 leads
to a decreased level of MEIS1 protein, and this decrease is prevented by inhibition of the proteasome.
Conclusions/Significance: Taken together, our data provide evidence for a dual mechanism of how PDX-1 negatively
regulates Krt19 ductal specific gene expression. These findings imply that transcription factors may efficiently regulate
target gene expression through diverse, non-redundant mechanisms.
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Introduction
The pancreas is a multifunctional organ that comprises an
endocrine compartment, which regulates glucose homeostasis
mainly through insulin secretion and is responsible for the
secretion of other hormones, and an exocrine compartment,
where acinar cells produce digestive enzymes that are secreted into
the intestine via a network of pancreatic ducts. Each distinct cell
type of the pancreas (endocrine, acinar and ductal) originates from
a common pool of progenitor cells during development and
requires a complex pattern of transcription factors [1] as well as
mesenchymal-epithelial interactions [2] for proper lineage speci-
fication. In the mouse, dorsal and ventral pancreatic buds start as
outgrowths from the foregut endoderm on day E9.5 [3], branch
and then fuse at E12 to E13. Functional cells can be observed at
day E14.5 [4].
The Pancreatic and Duodenal homeobox protein PDX-1 is
critical for pancreatic development. It is expressed in the foregut
endoderm at E8.5, prior to the onset of bud formation and
embryonic deletion of PDX-1 results in pancreatic agenesis [5]. In
addition to its crucial functions during development, PDX-1 is also
required for accurate endocrine function by regulating endocrine
gene expression [6] and b-cell survival in the adult [7]. Recent
three-dimensional cell culture studies have revealed the role of
PDX-1 in ductal branching morphogenesis or tubulogenesis, as it
appears to be re-expressed in otherwise PDX-1 negative
pancreatic ductal cells at the very site of branching [8]. Although
PDX-1 has been described as a positive regulator of gene
expression in endocrine cells, such as insulin and somatostatin,
recent evidence has shown that PDX-1 can be a negative regulator
of gene expression in non-endocrine pancreatic cells [9].
Keratins belong to the family of intermediate filament proteins
and are critical for proper tissue function and maintenance [10].
The family of keratins consists of 54 genes and can be classified
into type I (acidic) or type II (basic to neutral) keratins [11,12].
Typically, one type I keratin forms a heterodimer with a type II
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simple epithelial cells. In the pancreas, its expression is restricted to
ductal cells and is absent in acinar or endocrine cells. We have
demonstrated previously that Krt19 expression is regulated through
KLF4 and Sp1 transcription factors and that differences in
distribution of these factors in the pancreas are responsible for
ductal specific expression of Krt19 [13]. To investigate the
potential interplay between PDX-1 and ductal cell morphogenesis,
we have studied the impact of PDX-1 on Krt19 transcriptional
activity. In this study, we demonstrated transcriptional repression
of Krt19 by PDX-1. In addition, we identified the Hox co-factor
family of MEIS proteins as DNA binding partners on the Krt19
promoter [9].
MEIS (Myeloid ecotropic viral integration site) proteins are
members of the three amino acid loop extension (TALE)
homeodomain transcription factors and are required for the
proper DNA recognition by and the correct function of Hox
transcription factors [14]. Meis1 was first identified as a common
viral integration site in BXH-2 mice, which have nearly a 100%
rate of spontaneous leukemia [15]. Thereafter, the genes Meis2
and Meis3 were identified with a homology of 83% and 66%,
respectively, at the amino acid level. Additionally, several splice
variants exist for each gene. Of note, the Xaenopus laevis homologs
Xmeis1-1 and Xmeis1-2 share an amino acid sequence identity of
97% and 100% with MEIS1a, suggesting a highly evolutionarily
conserved function [16]. Indeed, Meis1 is essential for embryonic
development as Meis1 knockout mice die during embryogenesis
[17] due to hematopoietic and vasculature defects. However,
functional differences between the isoforms are not well under-
stood and require elucidation. Other members of the TALE
homeodomain transcription factors are PBX proteins that interact
with the FPWMK motif of Hox transcription factors. This is also
true for PDX-1 in pancreatic development as mutation of
FPWMK to AAGGQ in PDX-1 abrogates PBX binding and
results in pancreatic hypoplasia [18]. A similar phenotype is also
observed in Pbx1 knockout mice [19] underscoring the importance
of PDX-1/PBX1 interactions for pancreatic development.
Here, we set out (1) to characterize the domains of PDX-1
involved in Krt19 transcriptional repression, (2) to determine how
different Meis genes affect Krt19 transcriptional regulation and (3)
to elucidate functional interactions between MEIS proteins and
PDX-1. We provide evidence for the critical role of the NH2-
terminus of PDX-1 in mediating Krt19 repression. In addition,
MEIS1 is identified as the main isoform that is functionally
relevant in pancreatic ductal cells. MEIS1 binds directly to the
Krt19 promoter and knockdown of Meis1 mRNA, but not Meis2
mRNA, decreases Krt19 mRNA levels. In addition, we show co-
expression of MEIS1 and KRT19 in pancreatic ductal cells in vivo.
Surprisingly, PDX-1 over-expression leads to post-transcriptional
down-regulation of MEIS1 protein, which could be prevented by
inhibition of the proteasome, although this may potentially be
independent of ubiquitination. Taken together, our data suggest a
novel, dual mechanism of PDX-1 mediated regulation of Krt19
transcriptional activity, one directly through DNA binding and the
other through down-regulation of the Krt19 transcriptional
activator MEIS1.
Materials and Methods
Animals – Ethics Statement
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee of the University
of Pennsylvania (Protocol #800502). Six to eight week old
C57BL/6 mice were purchased at Charles River Laboratories
(Wilmington, MA) and housed according to institutional guidelines
for another week before experiments were performed.
Avidin-Biotin DNA precipitation assay
Avidin-Biotin DNA precipitation assay was essentially per-
formed as previously described [20]. Briefly, a total of 1000 mg
whole cell extract of cells transfected with pCMX, pCMX-PDX-1
V5 or pCMX-PDX-1 D1-37 V5, was incubated with 2 mg
biotinylated double stranded oligonucleotide for 4 hours with
constant rotation at 4uC in a total volume of 800 ml immunopre-
cipitation (IP) buffer (50 mM HEPES, 150 mM NaCl, 1 mM
EDTA, 0.5% NP-40, 10% glycerol). After addition of 60 mL
equilibrated streptavidin agarose beads (Invitrogen, Carlsbad, CA)
incubation was continued for 60 minutes at 4uC on a rotating
platform. Beads were collected by centrifugation and washed five
times with IP buffer. Precipitated beads were boiled in 26SDS-
sample buffer and proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). V5-epi-
tope was detected by Western blot. Densitometry was performed
directly on the Odyssey Infrared Imaging System (LiCor, Lincoln,
NE). Intensity of bands detected by V5 in the precipitation assay
was normalized to input samples. The following 59 biotinylated
oligonucleotides were used:
Krt19:5 9-biotin-GGGTGTGATTTCTAAGGGTGTCAAAT-
TCCTGGAGGT-39
Ins1:5 9-biotin-CTTATTAAGACTATAATAACCCTAAGA-
CTA-39
Scramble: 59-biotin-GCCGCCGCCGCCGCCGCCGC-3
For competition assays, unbiotinylated Krt19 oligonucleotide
was added in increasing concentrations (2, 10, 20, 50 and 100 mg),
and loading control was performed by Coomassie staining.
Plasmids
Deletions of PDX-1 were generated with a PCR based technique
using pCMX-PDX-1 as a template [9]. Primers were selected to
create full length PDX-1 or to delete amino acids (AA) 1–37, 1–109,
1–144, 260–284, and 235–284 and to add the coding sequence for
the V5-epitope in frame with the C-terminus. Restriction sites were
59-XhoI and 39-SacII. Following PCR amplification, coding
sequences were subcloned into pIRES2-EGFP. Subsequently, the
coding sequence of PDX-1 was removed from pCMX by restriction
with XhoI and BamHI and the V5-tagged inserts were subcloned
from the pIRES2-EGFP constructs back to pCMX using XhoI and
BamHI. Mutation of the pentapeptide motif of PDX-1
FPWMKRAAGGQ was introduced using Quikchange II XL Site
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to
the manufacturer’s instructions. MEIS1a was amplified from pCS2-
MEIS1a [9] and the coding sequence for FLAG was added in frame
with the C-terminus. For this purpose, NheI was used for 59-
restriction and XhoI for 39-restriction. The amplicon was then
inserted into pcDNA3.1(+) (Invitrogen, Carlsbad, CA). pcDNA-
MEIS2b-FLAG and pcDNA-MEIS3-FLAG were provided by Dr.
Doris A. Stoffers. The pM1, pM1 KOX-KRAB and pGL4.10
Gal4-TK plasmids were generous gifts of Dr. Frank J. Rauscher III
andhavebeen describedearlier[21].PDX-1andPDX-11–37were
fused to the GAL4-DNA-binding domain in pM1 by amplification
of PDX-1orPDX-1 1–37 from the PDX-1vectors described above,
using BamHI and SacII restriction sites. For insertion of 56Gal4
bindingmotifsinto pKrt19 -1970,unique AgeI and SacII restriction
sites were introduced at position 2367 bp upstream of the
transcriptional start site. Subsequently, the 5xGal4 binding motif
was removed from pIDTSMART 5xGal (Integrated DNA
Technologies, Coralville, IO) using AgeI and SacII and inserted
into pKrt19 -1970. pCMV-HA-Ubiqutin was a generous gift of Dr.
PDX-1 Regulates K19
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sequences used for cloning, generation of deletions or internal
mutations can be found in Table S1.
Cell culture and reagents
HEK 293T cells were purchased from ATCC (Manassas, VA)
and cultured in DMEM (Mediatech, Manassas, VA) supplemented
with 10% FBS (Sigma, St. Louis, MO) and 1% (w/v) penicillin/
streptomycin (Invitrogen, Calrsbad, CA). MIN6 mouse insulinoma
cells were provided by Dr. Doris A. Stoffers and cultured as
described previously [7]. Pancreatic ductal cells (PDCs) were
isolated and maintained as described [23].
Transfections, reporter assay, proteasome inhibition and
treatment with Trichostatin A (TsA)
For reporter studies, PDCs were plated in 12MW plates at a
density of 2610
4 cells and allowed to attach for 48 hrs. Cells were
then transfected using Lipofectamine 2000 and 0.38 mg of the
reporter construct (pGL3-basic, pKrt19 -1970 or pGal4-Krt19 -
1970), 0.02 mg pRL-CMV and 1.2 mg pCMX-PDX-1, truncated
versions of pCMX-PDX-1 or pM1GAL4-constructs. Fory-eight
hours post transfection cells were lysed in 100 ml passive lysis buffer
and assayed for luciferase activity using the Dual Luciferase Assay
Kit (Promega, Madison, WI). In a subset of experiments, treatment
with 0.3 mM TsA (Biomol, now part of ENZO Life Sciences,
Plymouth Meeting, PA) was performed 24 hrs. prior to the reporter
assay. For co-transfection studies, 5610
5 HEK 293T cells/well in a
6MW plate were seeded and transfected 24 hrs. later with 2 mgo f
each plasmid using Lipofectamine 2000. Inhibition of the protea-
some was achieved 48 hrs. post transfection by treating cells with
1 mM Bortezomib (LC Labs, Woburn, MA) or 5 mM MG-132
(Biomol, now part of ENZO Life Sciences, Plymouth Meeting, PA)
for indicated times. Small interfering RNAs (siRNAs) against Meis1
and Meis2 were purchased from Invitrogen (Carlsbad, CA), the
sequences were as follows: siMeis1 #15 9-TTGAGGCTGA-
CATTGGCATTCCAGG-39,s i Meis1 #25 9-TATGGCTTGA-
ATCATCAAGTTATCC-39,s i Meis2 #15 9-AATGTCATGC-
CAGCCAGCATGGGAT-39 and siMeis2 #2 5-TGGGCAC-
CCGTTGTTTCCTCTGTTA-39. Control siRNA was purchased
from Dharmacon, part # D-001206-13-05 (Lafayaette, CO).
siRNAs were transfected using the Amaxa Nucleofector and the
Amaxa Nucleofection Kit V. 240 pmol siRNA were transfected in
2610
6 PDCs in 100 ml Nucleofection solution V. Cells were
harvested 72 h post-transfection for RNA isolation.
Quantitative reverse-transcriptase PCR
RNA was isolated using the RNeasy kit (Quiagen, Maryland,
MD) and 1 mg was transcribed into cDNA (Taqman Reverse
Transcription Reagents, Applied Biosystems, Branchburg, NJ).
RNA was primed with random hexamers. Quantitative analysis
was carried out on an ABIPrism 7000 sequence detection system
and the amount of target gene was normalized to the endogenous
reference as described. [24,25]. Intron spanning isoform specific
primer sequences are listed in Table S2.
Immunoprecipitation-Electrophoretic Mobility Shift
Assay (IP-EMSA)
HEK 293T cells were plated in p100 dishes at a density of 5610
6
and transfected with pcDNA3.1(+), pcDNA-MEIS1a-FLAG,
pcDNA-MEIS2b-FLAG or pcDNA-MEIS3-FLAG using Lipofec-
tamine 2000 according to the manufacturer’s instructions. Forty-
eight hrs. post transfection cells were washed twice with PBS. Eight
hundred ml lysis buffer (50 mM TRIS pH 8.0, 150 mM NaCl, 1%
Nonidet-P 40) containing protease inhibitors (Roche, Indianapolis,
IN) were added subsequently. Cells were scraped, transferred to a
micro-centrifuge tube and allowed to lyse on ice for 10 min. After
clearing by centrifugation (10 min, 14000 rpm, 4uC), protein
concentration wasdeterminedbytheBradfordassay. 1.5 mgprotein
ina totalvolumeof 500 ml werepre-cleared for 1 h at4uCb ya d d i n g
60 mlofa 50%slurryofwashedprotein agaroseGbeads(Invitrogen,
Carlsbad, CA). Pre-cleared lysates were then incubated overnight at
4uCw i t h3mg anti-FLAG (Sigma, St. Louis, MO) or 3 mgc o n t r o l
non-immunogenic mouse IgG (Invitrogen, Carlsbad, CA). Samples
were prepared for EMSA as described earlier [26]. Briefly, the
immunoprecipitates were collected by centrifugation at 3,500 rpm
for 1 min at 4uC and washed five times with wash buffer (20 mM
HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 20% glycerol),
containing1%NP-40and oncewithwashbufferalone.Elutionfrom
beads was performed with 100 ml of 1.6% sodium deoxycholate in
wash buffer for 15 min on ice. The sodium deoxycholate was
neutralized with 12 ml of 10% NP-40, and the supernatant was
directly used for EMSA. 20 ml of the supernatant were used for
western blot analysis to confirm the efficiency of the IP.
EMSA
80 fmol of c
32P labeled oligonucelotide were incubated with the
supernatant for 20 min on ice in the presenceof 1 mg of anti-FLAG,
anti-MEIS1/2/3 (Millipore, Billerica, MA) or mouse control IgG in
a reaction mix containing 5% glycerol, 50 mM KCl, 1 mM EDTA,
10 mM TRIS, 50 ng/ml poly(dI-dC) and 1 mM DTT. Complexes
were resolved on a 5% polyacrylamid gel in 0.56TBE buffer for
90 min at 200 V. The gels were then dried and exposed on X-ray
film at 280uC. The Krt19 promoter fragment used in this assay was
59-CTAAGGGTGTCAAATTCCTG-39.
Western Blot analysis
Cells were lysed in IP buffer and protein concentration was
normalized using Bradford reagent (Biorad, Hercules, CA). 25 mg
were resolved on 4–12% Bis-Tris gels (Invitrogen, Carlsbad, CA),
and transferred to polyvinylidene difluoride membranes (PVDF) as
described. Membranes were blocked in either PBS containing
0.05%Tween and 5%non-fat dry milkorinblockingbuffer(LiCor,
Lincoln, NE) for 1 h at room temperature and incubated with one
of the following antibodies at 4uC overnight: anti-FLAG (Sigma, St.
Louis, MO) 1:1000, anti-V5 (Invitrogen, Carlsbad, CA) 1:5000,
anti-MEIS1/2/3, clone 9.2.7 (Millipore, Billerica, MA) 1:1000,
anti-b-actin (Sigma, St. Louis, MO) 1:5000, anti-PDX-1 A-17
(Santa Cruz Biotechnologies, Santa Cruz, CA) 1:500, anti-Cip/Waf
(BD Biosciences, Franklin Lakes, NJ) 1:1000. Visualization was
performed with either the appropriate HRP-coupled secondary
antibody (GE Healthcare, Piscataway, NJ) and Western Lightning
ECL reagents (Perking Elmer, Waltham, MA) on Hyperfilm ECL
(GE Healthcare) or with the Odyssey Infrared Imaging System
using IRDye 680 secondary antibodies (LiCor, Lincoln, NE).
Immunoprecipitation
HEK 293T were transfected with pCMV-HA-Ubiquitin,
pCDNA-MEIS1a-FLAG and pCMX-PDX-1 in equal amounts.
Forty-eight hours post transfection cells were treated with either
DMSO or Bortezomib (1 mM). IP and SDS-PAGE were
essentially performed as described previously [20]. Briefly, cells
were lysed in 800 ml lysis buffer (50 mM TRIS pH 8.0, 150 mM
NaCl, 1% Nonidet-P 40) containing protease inhibitors (Roche,
Indianapolis, IN). 1.5 mg protein in a total volume of 500 ml was
pre-cleared for 1 h at 4uC by adding 60 ml of a 50% slurry of
washed protein agarose beads (Invitrogen, Carlsbad, CA). Protein
A agarose was used for antibodies produced in rabbit, Protein G
PDX-1 Regulates K19
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then incubated overnight at 4uC with one of the following
antibodies: anti-V5, anti-HA (Santa Cruz Biotechnologies, Santa
Cruz, CA) or anti-FLAG. Proteins were separated by SDS-PAGE
and detected by appropriate HRP-coupled secondary antibodies.
Immunofluorescence staining
Eight to ten week old C/BL6 mice were sacrificed and the
pancreas was removed quickly and fixed overnight in 4% para-
formaldehyde. Organs were then embedded in paraffin, sectioned
at 4 mm and mounted on glass slides. Following standard
dewaxing and dehydration procedures, antigen retrieval was
performed by microwaving the sections for 12 minutes at 600 W
in buffered citric acid (pH 6.0). After permeabilization and
blocking, sections were incubated overnight with the following
antidodies: Keratin 19 (TROMA III, University of Iowa), MEIS1
(Abcam, Cambridge, MA, ab19867) and/or PDX-1 A-17 (Santa
Cruz Biotechnologies, Santa Cruz, CA). Visualization was
performed by incubation with Cy2 or Cy3 labeled appropriate
secondary antibodies (Jackson Immunoresearch, West Grove, PA,
1:600). Nuclear staining was achieved using 49,6-Diamidino-2-
phenylindole dihydrochloride (DAPI) (Sigma, St. Louis, MO).
Images were obtained using a Nikon E 600 microscope (Nikon
Instruments, Inc., Melville, NY) equipped with a Qicam Fast 1394
camera (Qimaging, Surrey, Canada) and iVision software
(BioVision Technologies, Exton, PA).
Statistics
A Student’s t-test was used for simple comparisons. Analysis of
variance (ANOVA) and Dunnett’s post-test were performed in
experiments that involved multiple comparisons. GraphPad Prizm
Software built in analysis tools were used for all statistical analyses.
Ap ,0.05 was considered statistically significant.
Results
PDX-1 represses Krt19 reporter gene activation through
the NH2-terminus
We assessed the pKrt19-1970 reporter gene activation by co-
transfection of pancreatic ductal cells (PDC) with empty vector or
full length PDX-1. Krt19 reporter gene activation was reduced by
74.962.1% (p,0.05) in the presence of PDX-1 as compared to
mock transfection (Fig. S1). These data are in line with previous
findings [9]. To characterize the PDX-1 domains required for
Krt19 repression we generated PDX-1 mutants with deletions of
the NH2- terminus (D1–37, D1–109 and D1–144), deletions of the
COOH-terminus (D260–284 and D235–284) and an internal
mutation of the amino acid sequence FPWMK to AAGGQ,
thereby abrogating possible interaction of PDX-1 with PBX
proteins in the latter PDX-1 mutant (Fig. 1A). Proper expression of
all constructs was confirmed by western blot analysis (Fig. 1B).
Deletion of the NH2-terminus resulted in significant relief of Krt19
repression by PDX-1. Interestingly, the deletion of the very first 37
Figure 1. PDX-1 represses Krt19 reporter gene activation through its NH2-terminus. A) Schematic overview of PDX-1 deletions and
mutations. B) Western blot using an antibody against the V5-epitope demonstrated equal expression of PDX-1 deletions/mutations C) PDCs were
transfected with pGL3 basic or pKrt19 -1970 reporter constructs and PDX-1 constructs shown in A). Reporter gene activity in cells transfected with
empty vector was set arbitrarily to 1.0. NH2 terminal deletion, but not COOH terminal deletion or FPWMK to AAGGQ mutation, abrogates Krt19
reporter gene repression. * p,0.05 as compared to PDX-1, significance was calculated by ANOVA and Dunnett’s multiple comparison tests.
doi:10.1371/journal.pone.0012311.g001
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PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12311Figure 2. The NH2-terminus of PDX-1 binds to Krt19 promoter DNA. A) MIN6 cells expressing endogenous PDX-1 were lysed and incubated
with one of the following biotinylated DNA fragments: Krt19-promoter, scrambled negative control DNA or insulin promoter (Ins1, positive control),
followed by precipitation with streptavidin agarose. Precipitated proteins and 2.5% input were separated with SDS-PAGE and blotted onto PVDF
membranes. Membranes were probed with anti-PDX-1. PDX-1 specifically bound to Krt19 and Insulin promoter DNA, but not scrambled negative
control DNA. B) Extracts of MIN6 cells were incubated with 2 mg of biotinylated Krt19 oligonucleotide and cold unbiotinylated Krt19 oligonucleotide
in increasing amounts as indicated [mg]. Separation of precipitated proteins was achieved by SDS-PAGE. Specifically precipitated PDX-1 was detected
using anti-PDX-1, non-specifically precipitated proteins served as a loading control and were visualized by Coomassie staining. C) MIN6 cells were
transfected with V5-tagged full length PDX-1 or PDX-1 D1-37. DNA precipitation was carried out as described above, and membranes were probed
with anti-V5. Deletion of the NH2-terminus of PDX-1 resulted in an almost complete loss of PDX-1 binding to the Krt19 promoter. D) PDX-1 negative
HEK 293T cells were transfected with V5-tagged full length PDX-1 or PDX-1 D1–37. DNA precipitation was carried out as described above, and
membranes were probed with anti-V5. PDX-1 D1–37 bound far less to the Krt19 promoter fragment. E) Quantification of DNA precipitation assays in
HEK 293T cells transfected with V5-tagged full length PDX-1 or PDX-1 D1–37. Band intensities were normalized to input levels prior to statistical
analysis. Deletion of the NH2-terminus resulted in a significant decrease of PDX-1 binding to the Krt19 promoter DNA. *p,0.05, Student t-test. F) PDCs
were transfected with either pGal4-Krt19 -1970 or pKrt19 -1970 and pGAL-KOX-KRAB, pGAL-PDX-1 or pGAL-PDX-1 1-37. Reporter gene activity in cells
PDX-1 Regulates K19
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deletion of the COOH-terminus or mutation of the PBX
interaction site had no effect on Krt19 repression (Fig. 1B).
The NH2-terminus of PDX-1 is important for binding to
the Krt19 promoter
To confirm binding of endogenous PDX-1 to Krt19 promoter
DNA, we performed DNA precipitation assays in PDX-1
expressing MIN6 cells employing a Krt19 promoter fragment that
has been previously shown to be relevant for Krt19 reporter gene
repression [9]. Using this DNA pulldown assay, we were able to
demonstrate interaction of endogenous PDX-1 with the Krt19
promoter. Binding of PDX-1 to Krt19 promoter DNA was specific
as shown by the complete absence of a signal in the scrambled
duplex control (Fig. 2A). As an additional proof of specificity we
performed a competition assay using a cold (unbiotinylated) Krt19
promoter fragment. Indeed, adding cold Krt19 olilgonucleotide in
increasing concentrations, as indicated, decreased binding of
PDX-1 to the biotin-labeled probe, confirming the specificity of
the assay (Fig. 2B). Next, we addressed the question whether
binding of PDX-1 to Krt19 promoter DNA is reduced upon
deletion of the NH2-terminus. To that end, MIN6 cells were
transfected with full length and PDX-1 D1–37. We found
markedly decreased binding of PDX-1 D1–37 to the Krt19
promoter fragment as compared to the full length PDX-1,
suggesting that interaction of PDX-1 with the Krt19 promoter
requires the NH2-terminus of PDX-1 (Fig. 2C). To rule out
possible competition of endogenous full length PDX-1 with
exogenous D1–37 PDX-1 in this system, full length and D1–37
PDX-1 were transfected in HEK 293T cells, which do not express
PDX-1. As expected, PDX-1 D1–37 displayed significantly
reduced binding to the Krt19 promoter (69.565.6% (p,0.05,
Figs. 2D, E).
To further investigate if the amino acids (AA) 1–37 of PDX-1
have the ability to serve as a portable repressor domain, we fused
full length PDX-1 and AA 1–37 to the DNA binding domain of
GAL4 and performed co-transfection experiments in PDCs using
a luciferase based reporter assay where the reporter is driven by a
thymidine kinase promoter containing a 5xGal4 motif. Using this
approach, we found that both full length PDX-1 and AA 1–37
increased reporter gene activation (data not shown). These
observations are in line with PDX-1 being an activator of multiple
genes, i.e. insulin or somatostatin and, more importantly, the fact
that the NH2-terminus of PDX-1 serves as a transactivating
domain on these target genes [27,28]. Interestingly, gene
activation through PDX-1 has been reported to require interaction
of co-activators like p300 with the NH2-terminus of PDX-1 [29].
These data led to the question if there is a potentially sequence
specific function of the PDX-1 NH2-terminus that mediates the
regulation of Krt19 transcription. To that end, we tested whether
GAL4-PDX-1 and GAL4-PDX-1 1–37 have an impact on the
activities of the wt-Krt19 promoter and a mutant version that
harbors a 5xGal4 motif. Surprisingly, both GAL4-PDX-1 and
GAL4-PDX-1 1–37 slightly, but still significantly, repressed Gal4-
Krt19 transcriptional activation (Fig. 2F), although to a far lesser
extent than the established repressor GAL4-KOX-KRAB [21,30].
However, GAL4-PDX-1 and GAL4-PDX-1 1–37 were able to
repress efficiently wt-Krt19 transcriptional activation (Fig. 2F),
whereas GAL4-KOX-KRAB was less effective. These data suggest
that targeting PDX-1 directly to Krt19 DNA impairs PDX-1’s
repressive function on transcriptional activation. By contrast, when
PDX-1 is allowed to choose freely the site of interaction and
possible interaction partners, it represses Krt19 transcriptional
activation. Most importantly this is also true for the amino acids
1–37 of PDX-1. Taken together, these data support the premise
that there is a DNA sequence specific repressive function of the
PDX-1 NH2-terminus, rather than a universal portable repressor
domain.
MEIS proteins bind to Krt19 promoter region in an
isoform-specific fashion
We further investigated the mechanism by which PDX-1 may
bind to the Krt19 promoter. Although we were unable to identify a
consensus TAA(T/T)TAT sequence for the binding of PDX-1
[31] the Krt19 fragment used for precipitation assays harbors a
MEIS binding site (Fig. 3A). This raised the question of whether
Krt19 expressing PDCs show different levels of MEIS proteins than
Krt19 negative PDX-1 positive endocrine MIN6 cells, and also
whether there is differential expression of Meis genes. We first
assessed mRNA levels of all three Meis genes in PDCs and MIN6
cells (Fig. 3B). We found significant differences in the mRNA levels
of Meis1, having a significantly higher expression in PDCs, and
Meis3, displaying a significantly higher expression in MIN6. Meis2
mRNA is equally expressed in both cell types. Second, we
evaluated expression of MEIS proteins by western blot (Fig. 3C).
PDX-1 negative PDCs show higher expression of MEIS proteins,
whereas PDX-1 positive MIN6 cells have overall lower levels of
MEIS expression. Additionally, both cell lines express different
MEIS proteins in line with the mRNA levels.
Due to the high sequence homology between MEIS proteins,
similar molecular masses and different splice variants, it is difficult
to precisely conclude which MEIS protein is detected by the
antibody that recognizes all three isoforms. Therefore, we
generated FLAG-tagged isoforms MEIS1a, MEIS2b and MEIS3
and transfected HEK 293T cells with either empty vector or
plasmids coding for each of the MEIS proteins. Immunoprecip-
itations were performed and eluted complexes were incubated
with radioactively labeled Krt19 promoter fragment as described in
the methods section. In this experiment, binding of MEIS1a and
to a lesser extent MEIS2b, but not MEIS3, to the Krt19 promoter
fragment was revealed (Fig. 3D). To validate this approach, a
supershift with anti-MEIS1/2/3 was performed. Co-incubation of
the FLAG-immunoprecipitates with anti-MEIS1/2/3 resulted in a
complete shift of MEIS1a and MEIS2b, whereas co-incubation
with non-immunogenic control IgG did not alter the mobility of
the complexes generated by MEIS1a and MEIS2b. The specificity
of the IP was demonstrated by the absence of a signal when the IP
was performed with IgG. To rule out possible variations caused by
different efficiencies of the IP, a fraction of the IP was separated by
SDS-PAGE and the membrane was probed with anti-FLAG
antibody (Fig. 3E). The result demonstrated equal efficiencies of
transfection and IP, suggesting specific DNA binding of MEIS1a
and MEIS2b, but not MEIS3 (Fig. 3D). Noteworthy, if EMSA was
performed directly with lysates of transfected cells, a shift could
only be observed for MEIS1a, but not MEIS2b, suggesting that
MEIS1a is the major MEIS protein that binds to the Krt19
promoter. (Fig. S3).
transfected with empty vector was arbitrarily set to 1.0. GAL4-PDX-1 and GAL4-PDX-1 1–37 repressed pGal4-Krt19 -1970 slightly and pKrt19 -1970
profoundly. *p,0.05 for samples transfected with pGal4-Krt19 -1970; **p,0.05 for samples transfected with pKrt19 -1970. Significance was calculated
by ANOVA and Dunnett’s multiple comparison tests.
doi:10.1371/journal.pone.0012311.g002
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PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12311Figure 3. MEIS binds to the Krt19 promoter in a homolog-specific fashion. A) Identification of a MEIS binding element in the Krt19 promoter
fragment. B) Quantitative Real-Time PCR was performed to detect Meis specific expression in PDX-1 negative PDCs and PDX-1 expressing MIN6 cells.
Meis1 and Meis3 show significant differential expression in both cell lines with higher expression of Meis1 in PDCs and higher levels of Meis3 in MIN6
cells, whereas Meis2 is expressed in equal amounts *p,0.05, Student’s t-test. C) Lysates obtained from PDCs and MIN6 cells were separated by SDS-
PAGE and transferred to PVDF membranes, which were probed with anti-MEIS1/2/3 antibody, anti-PDX-1 or anti-b-actin. Western blot analysis
revealed differential expression of MEIS proteins in these two cell lines. D) HEK 293T cells were transfected with FLAG-tagged MEIS1, MEIS2 or MEIS3.
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MEIS1a
Since homeobox proteins are capable of interacting with
members of the TALE homeodomain protein family, we evaluated
for possible protein-protein interactions between PDX-1 and
MEIS1a by co-transfection of HEK 293T cells. Surprisingly, co-
transfection resulted in absence of exogenous MEIS1a (Fig. 4A).
For visualization of expression kinetics PDX-1 was expressed from
a vector that co-expresses EGFP (Fig. 4B). Expression was
observed as early as 4 hrs. post transfection and peaked at
24 hrs. post transfection. To rule out possible promoter compe-
tition between expression vectors we evaluated PDX-1 expression
and endogenous MEIS1 expression at the indicated time points.
Indeed, endogenous MEIS1 was down-regulated with increasing
amounts of PDX-1 protein levels (Fig. 4C). To further elucidate
the nature of MEIS1 down-regulation, Meis1 mRNA levels were
measured by quantitative RT-PCR 36 hours post transfection.
Meis1 mRNA levels were not changed in the presence of PDX-1,
suggesting a possible posttranscriptional mechanism for MEIS1
regulation by PDX-1 (Fig. 4D). One possible mechanism in this
setting would be ubiquitination with proteasomal degradation of
MEIS1. To test this hypothesis, HEK 293T cells were co-
transfected with PDX-1 and MEIS1a and then treated with the
proteasome inhibitors MG-132 or Bortezomib. As before, co-
transfection of PDX-1 and MEIS1a led to down-regulation of
MEIS1a. However, this could be prevented by treatment with
MG-132 (Fig. 4E, upper panel) or Bortezomib (Fig. 4E, lower
panel). Stabilization of MEIS1a occurred in a time dependent
fashion, and efficiency of drug treatment was proven by
stabilization of the proteasomal regulated cell cycle protein p21.
To test the possibility that MEIS1a is degraded through
ubiquitination and subsequently the proteasome, we evaluated
MEIS1a for increased ubiquitination in the presence of PDX-1
with or without inhibition of the proteasome. Surprisingly, we
detected increased laddering for MEIS1a in the absence and the
presence of PDX-1, although to a lesser extent when PDX-1 was
present (Fig. S4A). We then performed co-immunoprecipitation
experiments with PDX-1, HA-tagged ubiquitin and FLAG-tagged
MEIS1a in order to validate these findings. Indeed, in the presence
of a proteasome inhibitor, HA-ubiquitin and FLAG-MEIS1a
interact in the absence of PDX-1. By contrast, in the presence of
PDX-1, an interaction could not be observed (Fig. S4B). Taken
together, these data suggest a mechanism where MEIS1a is
degraded by the proteasome in the presence of PDX-1, and this
may happen independently of ubiquitination. Interestingly, this
increased turnover of MEIS1a by PDX-1 does not appear to be
dependent upon the NH2-terminus of PDX-1 (Fig. S4C), thereby
indicating functional differences of PDX-1 with regards to binding
to the Krt19 promoter and the down-regulation of MEIS1a.
Meis1, but not Meis2, is critical for Krt19 transcriptional
activity in vitro and expressed in pancreatic ductal cells
in vivo.
Finally, we wanted to know whether Meis1 or Meis2 are
functionally relevant for Krt19 transcrtiptional regulation. To
address this question, Meis1 and Meis2 were genetically silenced in
PDCs using two different siRNAs against Meis1 or Meis2 and RNA
was extracted 72 h post transfection. Knockdown of Meis1 and
Meis2 was efficient and similar for each siRNA used (Fig. 5A and
S5A). Importantly, depletion of Meis1 (Fig. 5B), but not Meis2 (Fig.
S5B), resulted in significantly reduced Krt19 mRNA levels
(56.1163.74% and 65.77611.82%, respectively) indicating that
Meis1 is directly involved in the transcriptional control of Krt19 in
pancreatic ductal cells. To evaluate this in vivo, we performed
immunoflourescence staining on mouse pancreas for KRT19,
PDX-1 and MEIS1 using a MEIS1-specific antibody. As expected,
MEIS1 was expressed in pancreatic ducts together with KRT19,
but not PDX-1 (Fig. 5C). Although there appeared to be some
overlapping of KRT19 and MEIS1 (Fig. 5C), KRT19 staining was
found in the cytoplasm, whereas MEIS localized predominantly in
the nuclei of pancreatic ducts (Fig. 5D).
Taken together, our data indicate two mechanisms by which
Krt19 is regulated by PDX-1. The first one involves DNA binding
of PDX-1 to the Krt19 promoter that requires its NH2-terminus,
and the second one acts through down-regulation of MEIS1,
which is necessary for the maintenance of Krt19 mRNA levels.
Discussion
The goals of this study were to identify domains of PDX-1
necessary for mediation of Krt19 transcriptional repression and to
elucidate the functional interplay of PDX-1 with Hox-cofactors,
namely MEIS. We created several NH2 terminal and COOH
terminal deletions as well as an internal mutation of PDX-1. We
found that the NH2-terminus, but not the COOH terminus or the
pentapeptide motif, is critical in mediating Krt19 transcriptional
repression. The homeodomain, which was kept intact, harbors the
DNA binding site of PDX-1 and also the nuclear translocation
signal. Indeed, altered subcellular localization of PDX-1 does not
occur upon NH2 terminal deletion (Fig. S2) and cannot account
for the lack of repression of Krt19 by these mutants. In particular,
we demonstrated diminished binding of the PDX-1 NH2 terminal
deletion to the promoter DNA of Krt19. Our data obtained with
the GAL4 vector transfection studies support the premise that
there is a DNA sequence specific repressive function of the PDX-1
NH2-terminus, rather than this region of PDX-1 serving as a
universal portable repressor domain. Since direct binding of DNA
by PDX-1 occurs via the homeodomain, it cannot be excluded
that DNA binding mediated by the NH2-terminus is of an indirect
nature, possibly through protein-protein interactions. This notion
is supported by the fact that there is no canonical binding site for
PDX-1 within the Krt19 promoter.
Hox type transcription factors are known to bind to DNA either
alone or in association with co-factors. This can happen as either
heterodimeric or heterotrimeric complexes together with members
of the TALE family, such as PBX and MEIS [32,33]. PDX-1 has
been reported to interact with PBX proteins via the FPWMK
pentapeptide motif, and PBX in turn can recruit co-factors, such
as histone deacetylases (HDACs), in order to mediate transcrip-
tional repression [34].
We were able to exclude the involvement of PBX proteins in the
repression of Krt19 by PDX-1 through mutation of the PBX
interaction motif as described previously [18]. Furthermore,
Cells were lysed and immunoprecipitation using anti-FLAG was carried out. Precipitates were used for EMSA. IP against FLAG showed strong
occupancy on the Krt19 promoter fragment for MEIS1 and to a lesser extent for MEIS2, but not for MEIS3. Pre-incubation with anti-MEIS1/2/3 resulted
in a shift for MEIS1 and MEIS2. Control IP with IgG did not yield a band. E) 20 ml of the input used for EMSA were separated by SDS-PAGE and
transferred to PVDF membrane, followed by incubation with anti-FLAG. Western blot analysis showed equal amount of input and efficient pulldown
for each FLAG-tagged MEIS protein.
doi:10.1371/journal.pone.0012311.g003
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PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12311Figure 4. MEIS1 is regulated posttranscriptionally by PDX-1. A) HEK 293T cells were transfected with either MEIS1 or PDX-1 individually or in
combination. Cells were lysed, and expression of PDX-1 and MEIS1 was evaluated by western blot analysis. Co-expression of PDX-1 and MEIS1
resulted in the absence of MEIS1. B) HEK 293T cells were co-transfected with pIRES2-EGFP-PDX-1 to assess the time course of expression after
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PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12311treatment of cells with trichostatin A (TsA), an inhibitor of
HDACs, does not alleviate the PDX-1 mediated repression of
Krt19 (data not shown). This is consistent with a previous report
that the PDX-1 COOH-terminus is capable of recruiting HDACs
to regulate gene transcription [35].
Since PBX proteins do not participate in the repression of Krt19
by PDX-1 in a heterotrimeric complex consisting of PBX-PDX-1-
MEIS, we explored the possibility of a MEIS-PDX-1 heterodi-
meric complex. We identified a MEIS binding site in the Krt19
promoter and differential expression patterns of Meis genes with
transfection by EGFP. Brightfield and matching fluorescence images are shown at 2006 magnification. C) HEK 293T cells were transfected with
pIRES2-EGFP-PDX-1 and lysates were harvested at the indicated time points. Western blot analysis revealed down-regulation of endogenous MEIS1 in
a PDX-1 dependent manner. D) RNA was isolated 36 hrs. post transfection from HEK 293T cells that were transfected with PDX-1. Quantitative Real-
Time PCR demonstrated stable mRNA levels of endogenous MEIS1. E) HEK 293T cells were transfected with MEIS1 and either empty vector control or
PDX-1 and treated with DMSO or MG-132 or Bortezomib, respectively. Cells were lysed at indicated time points and subjected to western blot
analysis. Both, MG-132 and Bortezomib were able to stabilize MEIS1 protein levels in the presence of PDX-1. p21 was unaffected by PDX-1 and served
as a positive control for the functionality of MG-132 and Bortezomib, respectively.
doi:10.1371/journal.pone.0012311.g004
Figure 5. MEIS1 is essential for Krt19 transcription in vitro and is expressed in pancreatic ducts in vivo. A) and B) PDCs were transfected
with two different siRNAs against Meis1 and RNA was isolated 72 hrs. post transfection. Genetic silencing of Meis1 was efficient and resulted in a
significant decrease of Krt19 mRNA expression. *p,0.05. Statistical analysis was performed by ANOVA and Dunnett’s multiple comparison test. C)
Paraffin embedded mouse pancreatic tissue was stained for PDX-1, KRT19 and MEIS1 using a MEIS1 specific antibody. PDX-1 was expressed
exclusively in islets, and there was no co-expression of MEIS1 and PDX-1. MEIS1 stained ducts expressing KRT19 and was found in a large proportion
in the nuclei of ductal cells (arrowheads), whereas KRT19 was located in the cytoplasm (2006magnification). D) High power view of a pancreatic duct
shows MEIS1 predominantly locates within the nuclei of ductal cells. Arrowheads indicate non-nuclear MEIS1 signals (6006magnification).
doi:10.1371/journal.pone.0012311.g005
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expression in MIN6 cells. We confirmed MEIS1 and MEIS2 as
the major family members to bind the Krt19 promoter.
Interestingly, MEIS3, which displays only very low mRNA levels
in PDCs, does not bind to the Krt19 promoter. Meis1 and Meis2
might cooperate to regulate vertebrate retina development
through the maintenance of retinal progenitor cells [36]. That
Meis1 and Meis2 may be more important for the exocrine ductal
lineage is reinforced by the finding that the MEIS family members
PREP1 and PREP2 form much stronger binding complexes with
PBX1 on the Pax6 pancreatic enhancer during islet cell
development than do MEIS1 and MEIS2 [37].
To further understand the possible interaction between PDX-1
and MEIS1, we performed co-transfection experiments and found
down-regulation of MEIS1 protein in the presence of PDX-1 while
Meis1 mRNA remained at a constant level. Additionally, we
confirmed that the level of MEIS1 protein is inversely correlated
with PDX-1 expression levels and MEIS1 levels are dependent
directly on PDX-1 expression. For these reasons, we conclude that
MEIS1 down-regulation occurs on a posttranscriptional or basis.
One possible mechanism of how protein levels are regulated
posttranscriptionally is by increased turnover and degradation by
the proteasome. Indeed, MEIS1 protein could be stabilized in the
presence of PDX-1 through inhibition of the proteasome. However,
we were unable to demonstrate substantially increased ubiquitina-
tion of MEIS1 in the presence of PDX-1. One simple explanation
might be that the overall level of MEIS1 is reduced when PDX-1 is
present, which makes the detection of ubiquitinated MEIS1 difficult.
Another possibility that needs to be explored further is that the
degradation of MEIS1 through the proteasome is independent of
ubquitination, an exciting mechanism that has become increasingly
recognized [38] and has been described for important and well-
studied transcription factors, such as c-Fos, p53 and p73 [39,40,41].
Taken together, our data suggest different ways of how PDX-1
mediates the transcription of Krt19. First, we provide evidence for
directrepression throughbinding tothe Krt19 promoter,and second,
PDX-1 fosters proteasomal degradation of MEIS1. Third, we have
demonstrated that MEIS1 is a regulatory transcription factor that is
necessary for Krt19 transcriptional activation in PDCs. Since Meis2
knockdown does not affect Krt19 mRNA, we believe Meis2 does not
have a predominant role when compared to Meis1.
The regulation of MEIS1 is poorly understood, although there
is evidence for transcriptional regulation by Creb [42]. Here, we
show for the first time that MEIS1 appears to be posttranscrip-
tionally regulated by a mechanism that requires PDX-1. One
scenario might be the activation of an as yet unidentified MEIS1
interacting factor by PDX-1. We have shown previously that
MEIS1 activates the Krt19 promoter, and importantly, that this
property could not overcome PDX-1 mediated repression of Krt19
[9]. We now conclude that the posttranscriptional down-
regulation of MEIS1, both endogenous and exogenous, is
responsible for this effect.
A possible mechanism for up-regulation of MEIS target genes is
suggested by the recent finding that MEIS proteins increase the
histone H4 acetylation status on certain promoters during zebrafish
embryogenesis [43]. In this context, MEIS acts by regulating the
access of HDAC and CBP to such promoters. Consequently, loss of
MEIS1 would result in decreased transcriptional activity of critical
target genes. For example, zebrafish embryos lacking Meis1 have a
marked reduction in gata1 expression, which is critical for erythroid
cell fate, and lack circulating blood cells [44]. This can be observed in
the direct regulation of the developmentally important SOX3 by
MEIS1 and PBX [45]. Given the overall importance of PDX-1
during development and differentiation of the pancreas, it is tempting
to speculate that continued expression of PDX-1 would lead to
increased turnover of MEIS1 and prevent expression of Krt19 in the
endocrine lineage. Down-regulation of Krt19 transcription may then
be further secured by direct interference of PDX-1 with the Krt19
promoter in the ductal lineage; indeed, PDX-1 is down-regulated or
absent in differentiated ductal cells. Loss of PDX-1 could lead to
s t a b i l i z a t i o no fM E I S 1 ,r e l i e fo fr e p r e s s i o na tt h eKrt19 promoter and
subsequent ductal specific Krt19 gene expression (Fig. 6). This model
would complement the observation that regulated loss of PDX-1 at
mid-pancreatic development may still lead to the formation of a
truncated ductal tree, but not of acinar tissue [46].
Supporting Information
Table S1 Sequences of primers that have been used for the
generation of PDX-1 mutants and mutation of pKrt19-1970.
Primer sequences were selected to generate the indicated
truncation or mutation of PDX-1 of for fusion of PDX-1 and
Figure 6. Proposed model of how PDX-1 regulates Krt19 transcriptional activity. In a pancreatic duct cell, PDX-1 is not expressed and MEIS1
is able to occupy the Krt19 promoter and transactivate Krt19 transcription (left panel). By contrast, PDX-1 leads to displacement of MEIS1 from the
Krt19 promoter and its degradation by the proteasome through mechanisms not yet fully elucidated. PDX-1 in turn binds to the Krt19 promoter via its
NH2 terminal domain and consequently represses Krt19 transcriptional activation (right panel).
doi:10.1371/journal.pone.0012311.g006
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PLoS ONE | www.plosone.org 11 August 2010 | Volume 5 | Issue 8 | e12311PDX-1 1-37 to the GAL4 DNA binding domain. The primer
pKrt19 -1970 was used to introduce AgeI and SacII restricion sites
into pKrt19 -1970. Sequences in lower case introduced the desired
mutations.
Found at: doi:10.1371/journal.pone.0012311.s001 (0.04 MB
DOC)
Table S2 Primers for quantitative RT-PCR. Primers for
quantitative RT-PCR were designed for the specific mRNA as
indicated. Sequences were selected to be intron-spanning to avoid
amplification of genomic DNA.
Found at: doi:10.1371/journal.pone.0012311.s002 (0.03 MB
DOC)
Figure S1 Expression of PDX-1 in PDCs reduces Krt19
transcriptional activation. PDCs were transfected with either
pCMX or PDX-1 together with pGL3 basic or pKrt19-1970
luciferase reporter construct. Expression of PDX-1 resulted in
significant decrease of the luciferase reporter activity.
Found at: doi:10.1371/journal.pone.0012311.s003 (0.21 MB TIF)
Figure S2 Proper subcellular localization of PDX-1 is main-
tained upon NH2 terminal deletion. HEK 293T cells were
transfected with either empty vector, PDX-1 or PDX-1 D 1-37
and stained with anti-V5 antibody. Deletion of amino acids 1–37
does not affect translocation of PDX-1 to the nucleus (6006).
Found at: doi:10.1371/journal.pone.0012311.s004 (1.29 MB TIF)
Figure S3 MEIS1 binds to the Krt19 promoter DNA. HEK
293T cells were transfected with FLAG-tagged MEIS proteins
MEIS1, MEIS2 and MEIS3. A supershift was performed using
anti-FLAG antibody. A bandshift was observed when Krt19
promoter DNA was incubated with lysates from MEIS1 expressing
cells (arrow), but not from MEIS2 or MEIS3 expressing cells. Of
note, the band obtained with lysates from MEIS2 expressing cells
is distinct in size than the one observed with lysates from cells that
expressed MEIS3 or control cells.
Found at: doi:10.1371/journal.pone.0012311.s005 (3.47 MB TIF)
Figure S4 PDX-1 does not substantially increase ubiquitination
of MEIS1. A) HEK 293T cells were co-transfected with empty
vector or PDX-1 and MEIS1-FLAG and treated with DMSO or
proteasome inhibitors as indicated for 8 hrs. Follwing SDS-PAGE
and protein transfer to PVDF membranes, visualization was
perfomed by HRP-coupled secondary antibodies. Long exposure
(3 minutes) revealed markedly increased laddering of MEIS1 in
mock transfected samples and slightly increased laddering in the
presence of PDX-1 when samples were treated with proteasome
inhibitors. p21 served as a control for the efficiency of the drugs. B)
HEK 293T cells were transfected with equal amounts of pCMV-
HA-ubiquitin, PDX-1 and MEIS1a-FLAG. IP revealed interac-
tion of ubiqutin and MEIS1 in absence, but not in presence of
PDX-1, when samples were treated with the proteasome inhibtor
Bortezomib (1 mM). Notably, MEIS1 levels were reduced in
samples co-transfected with PDX-1, either with or without
inhibition of the proteasome as revealed by short exposure and
input, respectively. C) The down-regulation of MEIS1 by PDX-1
occurs independently of the C-terminus of PDX-1.
Found at: doi:10.1371/journal.pone.0012311.s006 (1.66 MB TIF)
Figure S5 Meis2 is not required for the regulation of Krt19.
PDCs were transfected with two different siRNAs against Meis2
and RNA was isolated 72 hrs. post-transfection. A) Knockdown of
Meis2 using two independent siRNA was highly efficient. B)
Despite sufficient knockdown of Meis2, Krt19 mRNA levels did not
change significantly. *p,0.05. Statistical analysis was performed
by ANOVA and Dunnett’s multiple comparison test.
Found at: doi:10.1371/journal.pone.0012311.s007 (0.35 MB TIF)
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